

Evaluation of a mosaic HIV-1 vaccine in a multicentre, r
placebo-controlled, phase 1/2a clinical trial (APPROACH

Lancet, The

392, 232-243

DOI: 10.1016/s0140-6736(18)31364-3

Citation Report

#	ARTICLE	IF	CITATIONS
1	Human Vaccines & Immunotherapeutics: News. Human Vaccines and Immunotherapeutics, 2018, 14, 2099-2100.	3.3	0
3	HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth. Retrovirology, 2018, 15, 74.	2.0	26
4	Post-translational Modification-Based Regulation of HIV Replication. Frontiers in Microbiology, 2018, 9, 2131.	3.5	31
5	Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy. Vaccine, 2018, 36, 6744-6751.	3.8	15
6	A new step towards an HIV/AIDS vaccine. Lancet, The, 2018, 392, 192-194.	13.7	9
7	<scp>HIV</scp>/<scp>AIDS</scp> Vaccines: 2018. Clinical Pharmacology and Therapeutics, 2018, 104, 1062-1073.	4.7	32
8	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. Animals, 2019, 9, 526.	2.3	11
9	â€Mosaicâ€™™ HIV vaccine to be tested in thousands of people across the world. Nature, 2019, 572, 165-166.	27.8	8
10	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. Vaccines, 2019, 7, 82.	4.4	11
11	Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia. Journal of Virology, 2019, 93, .	3.4	19
12	Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice. Frontiers in Immunology, 2019, 10, 1429.	4.8	6
13	Moving the HIV vaccine field forward: concepts of protective immunity. Lancet HIV,the, 2019, 6, e406-e410.	4.7	1
14	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Reports, 2019, 28, 877-895.e6.	6.4	36
15	Impact of HIV-1 Diversity on Its Sensitivity to Neutralization. Vaccines, 2019, 7, 74.	4.4	17
16	Novel prime-boost vaccine strategies against HIV-1. Expert Review of Vaccines, 2019, 18, 765-779.	4.4	34
17	Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials. Expert Review of Vaccines, 2019, 18, 1029-1041.	4.4	26
18	Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization. Cell Reports, 2019, 29, 1756-1766.e8.	6.4	47
19	CD8 + Cytotoxic-T-Lymphocyte Breadth Could Facilitate Early Immune Detection of Immunodeficiency Virus-Derived Epitopes with Limited Expression Levels. MSphere, 2019, 4, .	2.9	3

#	ARTICLE	IF	CITATIONS
20	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	26
21	Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor. <i>Science Advances</i> , 2019, 5, eaax3567.	10.3	69
22	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	4.8	32
23	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	46
24	A Sample-Sparing Multiplexed ADCP Assay. <i>Frontiers in Immunology</i> , 2019, 10, 1851.	4.8	42
25	Therapeutic Potential and Biological Applications of Cordycepin and Metabolic Mechanisms in Cordycepin-Producing Fungi. <i>Molecules</i> , 2019, 24, 2231.	3.8	61
26	Effect of Fc Receptor Genetic Diversity on HIV-1 Disease Pathogenesis. <i>Frontiers in Immunology</i> , 2019, 10, 970.	4.8	10
27	Current advances in HIV vaccine preclinical studies using Macaque models. <i>Vaccine</i> , 2019, 37, 3388-3399.	3.8	16
28	Immune Correlates of Disease Progression in Linked HIV-1 Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1062.	4.8	14
30	The Antibodiome—Mapping the Humoral Immune Response to HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 169-179.	3.1	13
31	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. <i>Journal of Virology</i> , 2019, 93, .	3.4	37
32	Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 91.	3.9	10
33	Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. <i>Nature Communications</i> , 2019, 10, 741.	12.8	46
34	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	18
35	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
36	Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations. <i>Npj Vaccines</i> , 2019, 4, 54.	6.0	27
37	Clinical and evolutionary consequences of HIV adaptation to HLA. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 194-204.	3.8	6
38	HIV-1 phylogenetics and vaccines. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 227-232.	3.8	6

#	ARTICLE	IF	CITATIONS
39	Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 253-264.	3.8	10
40	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. <i>Vaccines</i> , 2019, 7, 209.	4.4	25
41	Î±vÎ²3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26. <i>Journal of Virology</i> , 2019, 93, .	3.4	27
42	Global and regional molecular epidemiology of HIV-1, 1990â€“2015: a systematic review, global survey, and trend analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 143-155.	9.1	255
43	T cell-based strategies for HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 713-722.	3.3	39
44	Targeting Antigen to the Surface of EVs Improves the InÂVivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 108-125.	4.1	34
45	Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology. <i>Vaccine</i> , 2020, 38, 187-193.	3.8	5
46	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet</i> , The, 2020, 395, 384-388.	13.7	44
47	Recent insights into Fc-mediated effector responses to HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 282-289.	3.8	11
48	Advances in simianâ€“human immunodeficiency viruses for nonhuman primate studies of HIV prevention and cure. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 275-281.	3.8	7
49	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	28.9	25
50	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , the, 2020, 7, e688-e698.	4.7	58
51	Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2033-2041.	3.3	2
52	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 95, .	3.4	5
53	Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. <i>Npj Vaccines</i> , 2020, 5, 91.	6.0	286
54	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	27.8	765
55	Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada. <i>BMC Public Health</i> , 2020, 20, 1081.	2.9	1
56	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020, 5, 107.	6.0	11

#	ARTICLE	IF	CITATIONS
57	Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1744.	4.8	4
58	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020, 10, 13031.	3.3	10
60	The need to reassess our approaches at HIV cure and prevention. <i>Aids</i> , 2020, 34, 2141-2143.	2.2	2
61	Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey. <i>Lancet HIV</i> , 2020, 7, e772-e781.	4.7	51
62	A Zigzag but Upward Way to Develop an HIV-1 Vaccine. <i>Vaccines</i> , 2020, 8, 511.	4.4	5
63	Review of preventative HIV vaccine clinical trials in South Africa. <i>Archives of Virology</i> , 2020, 165, 2439-2452.	2.1	18
64	Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26 and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 595-607.	4.0	27
65	Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1001-1046.	3.1	7
66	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , 2020, 20, 1061-1070.	9.1	36
67	Therapeutic Vaccines for the Treatment of HIV. <i>Translational Research</i> , 2020, 223, 61-75.	5.0	14
68	The search for an HIV vaccine, the journey continues. <i>Journal of the International AIDS Society</i> , 2020, 23, e25506.	3.0	13
69	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. <i>Frontiers in Immunology</i> , 2020, 11, 984.	4.8	9
70	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	6.4	43
71	Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. <i>Future Drug Discovery</i> , 2020, 2, FDD25.	2.1	1
72	Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. <i>Frontiers in Immunology</i> , 2020, 11, 909.	4.8	96
73	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	30.7	43
74	Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost. <i>Vaccines</i> , 2020, 8, 106.	4.4	10
75	COVID-19 Vaccines: ‘Warp Speed’ Needs Mind Melds, Not Warped Minds. <i>Journal of Virology</i> , 2020, 94, .	3.4	79

#	ARTICLE	IF	CITATIONS
76	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq0 4.0 rgBT / Overlock 10	4.0	19
77	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. Cell Reports, 2020, 30, 1553-1569.e6.	6.4	21
78	CD8+ T cells in HIV control, cure and prevention. Nature Reviews Immunology, 2020, 20, 471-482.	22.7	163
79	Persistence of vaccine-elicited immune response up to 14Âyears post-HIV gp120-NefTat/AS01B vaccination. Vaccine, 2020, 38, 1678-1689.	3.8	2
80	Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges. Expert Review of Vaccines, 2020, 19, 133-142.	4.4	19
81	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Review of Vaccines, 2020, 19, 71-84.	4.4	12
82	Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope. Vaccines, 2020, 8, 64.	4.4	11
83	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annual Review of Immunology, 2020, 38, 673-703.	21.8	74
84	A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Vaccines, 2020, 8, 171.	4.4	6
85	Adenoviral Vectors Meet Gene Editing: A Rising Partnership for the Genomic Engineering of Human Stem Cells and Their Progeny. Cells, 2020, 9, 953.	4.1	19
86	Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged â‰¥60 Years. Journal of Infectious Diseases, 2020, 222, 979-988.	4.0	78
87	A primer to gene therapy: Progress, prospects, and problems. Journal of Inherited Metabolic Disease, 2021, 44, 54-71.	3.6	9
88	Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. Journal of Infectious Diseases, 2021, 223, 370-380.	4.0	50
89	Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 2021, 39, 3081-3101.	3.8	51
90	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
91	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	30.7	473
92	Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. Journal of Infectious Diseases, 2021, 223, 699-708.	4.0	43
94	HIV vaccinology: 2021 update. Seminars in Immunology, 2021, 51, 101470.	5.6	31

#	ARTICLE	IF	CITATIONS
95	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , 2021, 371, 521-526.	12.6	88
96	Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. <i>Npj Vaccines</i> , 2021, 6, 15.	6.0	5
97	Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	8
98	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. <i>Comparative Medicine</i> , 2021, 71, 411-432.	1.0	11
99	Evidence of a tolerogenic vaccine against AIDS in the Chinese macaque prefigures a potential human vaccine. <i>Archives of Virology</i> , 2021, 166, 1273-1282.	2.1	1
100	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 202-209.	8.2	110
101	HIV-1 Envelope Glycosylation and the Signal Peptide. <i>Vaccines</i> , 2021, 9, 176.	4.4	5
102	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. <i>Journal of Immunology</i> , 2021, 206, 1266-1283.	0.8	8
103	Lack of Molecular Mimicry between Nonhuman Primates and Infectious Pathogens: The Possible Genetic Bases. <i>Global Medical Genetics</i> , 2021, 08, 032-037.	0.9	3
104	Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262.	4.4	3
105	Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 657424.	4.8	2
106	COVID-19 vaccines: The status and perspectives in delivery points of view. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 1-25.	13.7	262
107	Novel approaches for vaccine development. <i>Cell</i> , 2021, 184, 1589-1603.	28.9	145
108	Ad26.COVS.2 protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. <i>Npj Vaccines</i> , 2021, 6, 39.	6.0	38
109	Adjuvant-mediated enhancement of the immune response to HIV vaccines. <i>FEBS Journal</i> , 2022, 289, 3317-3334.	4.7	10
110	To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. <i>Viruses</i> , 2021, 13, 805.	3.3	4
111	Emerging concepts in the science of vaccine adjuvants. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 454-475.	46.4	601
112	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	6.0	46

#	ARTICLE	IF	CITATIONS
113	The diversity of HIV-1 fights against vaccine efficacy: how self-assembling protein nanoparticle technology may fight back. <i>Nanomedicine</i> , 2021, 16, 673-680.	3.3	0
114	Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model. <i>Journal of Virology</i> , 2021, 95, .	3.4	7
115	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti- Zika Virus Vaccine. <i>Annals of Internal Medicine</i> , 2021, 174, 585-594.	3.9	44
116	Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice. <i>Journal of Virology</i> , 2021, 95, .	3.4	6
118	CMV, MHC-E, and the quest for an unconventional AIDS vaccine. <i>Science Immunology</i> , 2021, 6, .	11.9	2
119	The path to find an HIV vaccine. <i>Journal of the International AIDS Society</i> , 2021, 24, e25749.	3.0	6
120	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 678511.	4.8	11
121	Psychosocial Stress Alters the Immune Response and Results in Higher Viral Load During Acute Simian Immunodeficiency Virus Infection in a Pigtailed Macaque Model of Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 224, 2113-2121.	4.0	10
122	Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. <i>Viruses</i> , 2021, 13, 837.	3.3	7
123	Interim Results of a Phase 1a Trial of Ad26.COVS.2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 1824-1835.	27.0	962
124	Sustained viremia suppression by SHIVSF162P3CN-recalled effector-memory CD8+ T cells after PD1-based vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1009647.	4.7	2
125	Safety and Efficacy of Single-Dose Ad26.COVS.2 Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	27.0	1,954
126	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 697074.	4.8	18
127	Recent advances on smart glycoconjugate vaccines in infections and cancer. <i>FEBS Journal</i> , 2022, 289, 4251-4303.	4.7	39
128	Vaccine development lessons between HIV and COVID-19. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 759-761.	9.1	3
129	Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. <i>Viruses</i> , 2021, 13, 1351.	3.3	1
130	A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice. <i>Cell Reports Medicine</i> , 2021, 2, 100372.	6.5	16
131	Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases. <i>Vaccine</i> , 2021, 39, 5233-5239.	3.8	0

#	ARTICLE	IF	CITATIONS
132	Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials. JCO Global Oncology, 2021, 7, 1358-1363.	1.8	11
133	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. Journal of Clinical Investigation, 2021, 131, .	8.2	17
134	Shell-mediated phagocytosis to reshape viral-vectored vaccine-induced immunity. Biomaterials, 2021, 276, 121062.	11.4	12
135	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. ELife, 2021, 10, .	6.0	12
136	Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination. Journal of Virology, 2021, 95, e0092521.	3.4	9
137	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. Vaccines, 2021, 9, 1001.	4.4	2
138	Current Status of HIV-1 Vaccines. Vaccines, 2021, 9, 1026.	4.4	17
139	Polyfunctional Tier 2—Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. Journal of Immunology, 2021, 206, 999-1012.	0.8	5
140	Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations. Vaccine, 2021, 39, 580-587.	3.8	7
141	Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. Frontiers in Immunology, 2020, 11, 607333.	4.8	21
142	Peptides to combat viral infectious diseases. Peptides, 2020, 134, 170402.	2.4	42
143	Shortening HIV vaccine regimens to achieve high coverage. Lancet HIV, the, 2020, 7, e377-e378.	4.7	2
144	Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	45
145	Joint epitope selection and spacer design for string-of-beads vaccines. Bioinformatics, 2020, 36, i643-i650.	4.1	5
151	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. Journal of Clinical Investigation, 2019, 129, 4838-4849.	8.2	95
152	Graph-theoretical formulation of the generalized epitope-based vaccine design problem. PLoS Computational Biology, 2020, 16, e1008237.	3.2	6
153	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Medicine, 2020, 17, e1003117.	8.4	8
154	A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques. Npj Vaccines, 2021, 6, 123.	6.0	2

#	ARTICLE	IF	CITATIONS
155	Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. <i>Journal of Autoimmunity</i> , 2021, 125, 102742.	6.5	42
162	Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa606.	0.9	2
165	Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands. <i>Journal of Virus Eradication</i> , 2018, 4, 238-247.	0.5	3
166	Current approaches to HIV vaccine development: a narrative review. <i>Journal of the International AIDS Society</i> , 2021, 24, e25793.	3.0	35
167	Virus-based vaccine vectors with distinct replication mechanisms differentially infect and activate dendritic cells. <i>Npj Vaccines</i> , 2021, 6, 138.	6.0	2
168	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021, 17, e1010016.	4.7	1
169	Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People With and Without Human Immunodeficiency Virus: A Randomized Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
170	Viral Vector Vaccines. , 2021, , .		0
171	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. <i>Molecular Therapy</i> , 2022, 30, 2024-2047.	8.2	14
172	Una vacuna preventiva frente al VIH. Situación actual y perspectivas. <i>Revista De Investigación Y Educación En Ciencias De La Salud (RIECS)</i> , 2020, 5, 81-90.	0.0	0
173	Adenovirus-based vaccines as a platform for pandemic preparedness against emerging viral pathogens. <i>Molecular Therapy</i> , 2022, 30, 1822-1849.	8.2	24
174	So Pathogenic or So What? A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research. <i>Viruses</i> , 2022, 14, 135.	3.3	5
175	Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein. <i>Vaccine</i> , 2022, 40, 574-586.	3.8	15
176	Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates. <i>Vaccines</i> , 2022, 10, 187.	4.4	2
177	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. <i>Current HIV/AIDS Reports</i> , 2022, 19, 86.	3.1	6
178	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.	3.8	225
179	A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <i>Nature Medicine</i> , 2021, 27, 2234-2245.	30.7	80
180	Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19. <i>Viruses</i> , 2022, 14, 380.	3.3	4

#	ARTICLE	IF	CITATIONS
181	Peptides for Vaccine Development. ACS Applied Bio Materials, 2022, 5, 905-944.	4.6	26
182	Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. Toxins, 2022, 14, 138.	3.4	6
183	Human adenovirus type 26 basic biology and its usage as vaccine vector. Reviews in Medical Virology, 2022, 32, e2338.	8.3	4
184	HIV-1 infections with multiple founders associate with the development of neutralization breadth. PLoS Pathogens, 2022, 18, e1010369.	4.7	5
185	COVID-19 vaccination and HIV-1 acquisition – Authors’ reply. Lancet, The, 2022, 399, e36.	13.7	0
186	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. Journal of Virology, 2022, , e0003422.	3.4	7
187	Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine. Journal of Infectious Diseases, 2022, 226, 979-982.	4.0	7
201	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Npj Vaccines, 2022, 7, 53.	6.0	4
202	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunological Reviews, 2022, 310, 6-26.	6.0	138
203	Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis. BMJ Open, 2022, 12, e058795.	1.9	1
204	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. Journal of Immunology, 2022, 208, 2663-2674.	0.8	8
205	Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine. Immunological Reviews, 2022, 310, 47-60.	6.0	10
206	Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms, 2022, 10, 1450.	3.6	28
207	The use of viral vectors in vaccine development. Npj Vaccines, 2022, 7, .	6.0	73
208	CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies. Current Opinion in HIV and AIDS, 2022, 17, 315-324.	3.8	10
209	HIV Transmission Prevention. , 2021, , 30-50.		0
210	The HIV Reservoir and Cure and Remission Strategies. , 2021, , 199-217.		0
211	Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nature Reviews Immunology, 2023, 23, 142-158.	22.7	91

#	ARTICLE	IF	CITATIONS
212	HLA-II-Associated HIV-1 Adaptation Decreases CD4 ⁺ T-Cell Responses in HIV-1 Vaccine Recipients. <i>Journal of Virology</i> , 0, .	3.4	0
213	Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans. <i>Npj Vaccines</i> , 2022, 7, .	6.0	4
214	Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells. <i>EBioMedicine</i> , 2022, 84, 104253.	6.1	8
215	Developing capacity for implementation and evaluation of vaccine trials in Uganda: Perspective of the Makerere University Walter Reed Project. <i>African Health Sciences</i> , 2022, 22, .	0.7	0
216	Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	1
217	Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens. <i>PLoS Computational Biology</i> , 2022, 18, e1010624.	3.2	1
218	Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study. <i>Journal of Infectious Diseases</i> , 2023, 227, 939-950.	4.0	4
219	Structural analysis of Plasmodium falciparum ookinete surface antigen Pfs28 relevant for malaria vaccine design. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
220	Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets. <i>Npj Vaccines</i> , 2022, 7, .	6.0	0
221	Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2023, 1867, 130288.	2.4	4
222	Adaptation to HLA-associated immune pressure over the course of HIV infection and in circulating HIV-1 strains. <i>PLoS Pathogens</i> , 2022, 18, e1010965.	4.7	0
224	Ad26.COVS.2 and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques. <i>Cell Reports Medicine</i> , 2023, 4, 101018.	6.5	3
225	Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines. <i>Current Opinion in Immunology</i> , 2023, 80, 102282.	5.5	5
226	Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	4
227	Efficacy and Safety of an Ad26.RSV,preFâ€“RSV preF Protein Vaccine in Older Adults. <i>New England Journal of Medicine</i> , 2023, 388, 609-620.	27.0	41
228	Parainfluenza virus 5 is a nextâ€“generation vaccine vector for human infectious pathogens. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	3
229	Immune Response to HIV-1 Infection and Vaccine Development. , 0, , .		0
230	Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial. <i>Vaccine</i> , 2023, 41, 2696-2706.	3.8	2

#	ARTICLE	IF	CITATIONS
231	Nano-vaccines for gene delivery against HIV-1 infection. Expert Review of Vaccines, 2023, 22, 315-326.	4.4	1
232	CD8+ Lymphocytes from Healthy Blood Donors Secrete Antiviral Levels of Interferon-Alpha. Viruses, 2023, 15, 894.	3.3	0
233	Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases. Journal of Molecular Biology, 2023, 435, 168173.	4.2	7
235	Prevention, treatment and cure of HIV infection. Nature Reviews Microbiology, 2023, 21, 657-670.	28.6	21
236	An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates. International Journal of Molecular Sciences, 2023, 24, 9077.	4.1	0
237	A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses. Science Translational Medicine, 2023, 15, .	12.4	7
238	The Mechanism of bnAb Production and Its Application in Mutable Virus Broad-Spectrum Vaccines: Inspiration from HIV-1 Broad Neutralization Research. Vaccines, 2023, 11, 1143.	4.4	0
239	Elevated glutamate impedes anti-HIV-1 CD8 ⁺ T cell responses in HIV-1-infected individuals on antiretroviral therapy. Communications Biology, 2023, 6, .	4.4	1
240	Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study. Journal of Infectious Diseases, 0, , .	4.0	1
241	The Mosaico HIV Vaccine Study: A Step Back or a Stepping Stone for Future Vaccine Development?. , 2023, 2, 2.		1
242	Human Immunodeficiency Virus Vaccines. , 2023, , 458-483.e15.		0
243	The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma. Npj Vaccines, 2023, 8, .	6.0	0
244	BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine. IScience, 2023, 26, 107612.	4.1	0
245	Geographic and Population Distributions of Human Immunodeficiency Virus (HIV)â€1 and HIV-2 Circulating Subtypes: A Systematic Literature Review and Meta-analysis (2010â€2021). Journal of Infectious Diseases, 2023, 228, 1583-1591.	4.0	5
247	Anticipating HIV viral escape â€ resistance to active and passive immunization. Current Opinion in HIV and AIDS, 2023, 18, 342-348.	3.8	1
248	Guiding HIV-1 vaccine development with preclinical nonhuman primate research. Current Opinion in HIV and AIDS, 2023, 18, 315-322.	3.8	1
249	Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses. Current Opinion in HIV and AIDS, 2023, 18, 331-341.	3.8	1
250	Mosaic HIV-1 vaccination induces anti-viral CD8 ⁺ T cell functionality in the phase 1/2a clinical trial APPROACH. Journal of Virology, 0, , .	3.4	0

#	ARTICLE	IF	CITATIONS
252	Current Perspectives and Challenges of MAIT Cell-Directed Therapy for Tuberculosis Infection. Pathogens, 2023, 12, 1343.	2.8	0
253	Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines. Cell Reports, 2023, 42, 113292.	6.4	1
254	Highlights of the HIV cure session, 19th European AIDS Clinical Society (EACS) Conference, 18-21 October 2023, Warsaw, Poland. Journal of Virus Eradication, 2023, 9, 100359.	0.5	0
255	Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine. Journal of Virology, 2023, 97, .	3.4	0
257	Prophylactic HIV-1 vaccine trials: past, present, and future. Lancet HIV,the, 2024, 11, e117-e124.	4.7	1
259	Absolute quantitation of binding antibodies from clinical samples. Npj Vaccines, 2024, 9, .	6.0	0
260	AutoTransOP: translating omics signatures without orthologue requirements using deep learning. Npj Systems Biology and Applications, 2024, 10, .	3.0	0
261	Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial. EBioMedicine, 2024, 100, 104987.	6.1	0
262	Structural insights into the interaction between adenovirus C5 hexon and human lactoferrin. Journal of Virology, 2024, 98, .	3.4	0
263	HIV-1 Gag, Pol, and Env diversified with limited adaptation since the 1980s. MBio, 2024, 15, .	4.1	0
264	Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution. Engineering Microbiology, 2024, 4, 100140.	4.7	0
265	Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2. Journal of Nanobiotechnology, 2024, 22, .	9.1	0
266	Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIVâ€”workshop report. Npj Vaccines, 2024, 9, .	6.0	0
267	Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects. Viruses, 2024, 16, 368.	3.3	0
268	Strategies to target the central nervous system HIV reservoir. Current Opinion in HIV and AIDS, 2024, 19, 133-140.	3.8	0
269	Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention. Vaccines, 2024, 12, 298.	4.4	0